Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Oliver Sartor MD
Oliver Sartor MD Advisory Board
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · May 14, 2015

Trametinib Similar Activity to Docetaxel in KRAS-Mutant Advanced NSCLC

Annals of Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Annals of Oncology
A Randomized Phase II Study of the MEK1/MEK2 Inhibitor Trametinib (GSK1120212) Compared With Docetaxel in KRAS-Mutant Advanced Non-Small-Cell Lung Cancer (NSCLC)
Ann. Oncol 2015 May 01;26(5)894-901, GR Blumenschein, EF Smit, D Planchard, DW Kim, J Cadranel, T De Pas, F Dunphy, K Udud, MJ Ahn, NH Hanna, JH Kim, J Mazieres, SW Kim, P Baas, E Rappold, S Redhu, A Puski, FS Wu, PA Jänne

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated